Brett Goldsmith | Cardea Bio Inc: Can we detect DNA, antigens, and antibodies simultaneously on a single microchip without PCR?
00:10:10 - 00:12:32
Other snippets from this talk
Summary of the clip:
Can we detect DNA, antigens, and antibodies simultaneously on a single microchip without PCR?
Current diagnostic paradigms are heavily siloed, requiring separate workflows such as PCR for genomics, ELISA for proteomics, and serology for immunology. This segmentation limits clinical decision-making by missing the complex multi-omic interactions occurring in real-time within a patient.
Graphene field-effect transistors provide a chemically reconfigurable surface that can be functionalized with diverse capture probes, including CRISPR-Cas complexes, antibodies, and synthetic aptamers. This allows a single multi-channel chip to perform simultaneous DNA, antigen, and antibody detection on a single fluid sample.
By utilizing CRISPR-gated transistors, this platform can detect target genomic sequences and single nucleotide polymorphisms (SNPs) directly, completely bypassing the need for enzyme-driven target amplification. This eliminates the chemical bias and thermal cycler overhead typical of traditional molecular diagnostics.
In this short video, you can learn:
* How multi-channel graphene transistors enable simultaneous multi-omic detection of DNA, proteins, and antibodies.
* The mechanism of CRISPR-gated transistors for amplification-free genomic detection and SNP identification.
* Why eliminating PCR amplification reduces instrument footprint, assay time, and diagnostic overhead.
📋 **Clip Abstract** This clip presents Cardea Bio's breakthrough work in combining molecular diagnostics and immunochemical assays onto a single, reconfigurable graphene chip. It explains how CRISPR-gated transistors detect single nucleotide polymorphisms directly from samples without enzymatic amplification.
#GrapheneFieldEffectTransistors, #CRISPRGatedTransistors, #AmplificationFreeDetection, #MultiOmicBiosensors, #Bioelectronics, #PointOfCareDiagnostics
This is a highlight of the presentation:
More Highlights from the same talk.
00:01:59 - 00:03:29
Why is using light to look at DNA and proteins a fundamental mismatch of scale?
Why is using light to look at DNA and proteins a fundamental mismatch of scale?
Traditional biological interrogation relies heavily on optical methods, using light waves to examine interactions between cells, proteins, and nucleic acids. However, this creates a severe mismatch in spatial scale. Because light waves are much larger than proteins and DNA, direct optical reading is highly inefficient, forcing scientists to rely on artificial workarounds.
These workarounds include copying DNA millions of times via Polymerase Chain Reaction (PCR) or attaching massive chemical fluorescent labels to proteins. These invasive processes strip away crucial spatial and environmental context from the biological system and can physically disrupt native conformational kinetics.
By replacing optical sensors with direct charge-sensing graphene field-effect transistors (gFETs), we can bypass the need for labeling or amplification. This allows researchers to capture authentic, real-time molecular interactions in their native state and biological context.
In this short video, you can learn:
* The physical dimensional limitations of using optical light waves to interrogate nanometer-scale biomolecules.
* How PCR amplification and bulky fluorescent labels alter biological context and protein dynamics.
* The strategic advantage of using label-free graphene transistors to establish continuous, real-time multi-omic data streams.
📋 **Clip Abstract** This clip explains why current optical biology tools fall short due to dimensional mismatches between light waves and nanometer-scale biomolecules. It highlights how label-free graphene transistors can preserve vital biological context by eliminating the need for PCR amplification and target labeling.
#GrapheneFETs, #LabelFreeBiosensing, #ChargeSensing, #BiomolecularElectronics, #Bioelectronics, #MultiOmics
00:08:34 - 00:10:09
Why is semiconductor foundry integration only the first step in commercializing graphene biosensors?
Why is semiconductor foundry integration only the first step in commercializing graphene biosensors?
Many 2D material startups focus exclusively on achieving cleanroom wafer-scale fabrication. While silicon foundry integration is an absolute prerequisite to achieve the volume and consistency required for medical markets, it represents only the beginning of the commercialization pipeline.
Transitioning from a raw sensor die to a finished commercial product requires a massive engineering effort in packaging, fluidics, and instrumentation. Cardea Bio addressed this hurdle by building modular, Lego-block-style hardware reader boards, fluidics modules, and software infrastructure.
This architecture allows the same core graphene transistor chip to be deployed across diverse end-user instruments without costly ground-up re-engineering. This modular strategy is essential for navigating the highly fragmented life science and clinical diagnostics markets.
In this short video, you can learn:
* Why foundry wafer-scale integration is only the first step in launching a successful commercial 2D material product.
* The necessity of developing robust packaging, fluidic interfaces, and reading electronics for raw graphene dies.
* How modular, Lego-block system architectures dramatically lower engineering costs across diverse market segments.
📋 **Clip Abstract** This clip details the progression of Cardea Bio's graphene transistor platform from hand-built prototypes to foundry-fabricated chips. It explores the critical strategic need for modular packaging and reader systems to scale 2D material biosensors into fragmented commercial markets.
#GrapheneBiosensors, #GrapheneFET, #MicrofluidicPackaging, #ModularBioelectronics, #PointOfCareDiagnostics, #LabOnAChip